Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201

Abstract

We previously reported the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy (Jpn J Clin Oncol 2013). We sought to determine the clinical usefulness of a more convenient hydration method, evaluating the safety and efficacy of shorter-term and lower-volume hydration. Chemonaïve patients with advanced lung cancer who were ≤75 years and reserved an adequate renal function for cisplatin use (≥60 mg/m2) were eligible. An intravenously administered hydration of 1700 ml in ~3.5 h with 1500 ml of orally administered hydration was investigated. The primary endpoint was the proportion of patients without grade 2 or worse renal toxicity in the first cycle. A total of 45 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl, and the median cisplatin dose on day 1 was 75 mg/m2. In the first cycle, one patient (2 %) developed grade 2 creatinine toxicity, and thus, the proportion of patients with less than grade 2 was 98 % (the lower limit of 95 % confidence interval; 93 %), which met the primary endpoint. Five patients (11 %) had grade 1 or greater nephrotoxicity, three of whom successfully recovered. The objective response rate was 24 % and median progression-free survival 5.8 months. This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.

DOI: 10.1007/s10147-015-0860-1

6 Figures and Tables

020040020162017
Citations per Year

165 Citations

Semantic Scholar estimates that this publication has 165 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ninomiya2015ShorttermLH, title={Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201}, author={Kiichiro Ninomiya and Katsuyuki Hotta and Akiko Hisamoto-Sato and Eiki Ichihara and Hiroko Gotoda and Daisuke Morichika and Tomoki Tamura and Hiroe Kayatani and Daisuke Minami and Toshio Kubo and Masahiro Tabata and Mitsune Tanimoto and Katsuyuki Kiura}, journal={International Journal of Clinical Oncology}, year={2015}, volume={21}, pages={81-87} }